Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430

Alzheimer's Disease Dementia With Lewy Bodies Frontotemporal Dementia +1 more

ENROLLING_BY_INVITATION PHASE4

Tau PET Outcomes With Anti-amyloid Immunotherapies

NCT06723015

Cognitive Impairment, Mild Dementia, Mild Alzheimer Disease

ENROLLING_BY_INVITATION PHASE2

Imaging Tau in Alzheimer's Disease and Normal Aging

NCT03373604

Alzheimer Disease

COMPLETED PHASE2

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

NCT04680130

PSP CBD PCA +9 more

ENROLLING_BY_INVITATION

Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease

NCT01095744

Alzheimer's Disease Posterior Cortical Atrophy Logopenic Progressive Aphasia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atypical Alzheimer's Disease Logopenic Progressive Aphasia (LPA) Posterior Cortical Atrophy (PCA) Alzheimer Disease Alzheimer Disease, Early Onset Amnestic Disorder Amnestic Symptoms Amnestic Mild Cognitive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tau PET Scan, F-18 AV 1451

All subjects will receive two Tau PET scans during this study.

Group Type EXPERIMENTAL

F-18 AV 1451

Intervention Type DRUG

Tau binding agent

C-11 PiB

Intervention Type DRUG

Amyloid binding agent

PiB PET Scan, C-11 PiB

All subjects will receive two PiB PET scans during this study.

Group Type EXPERIMENTAL

F-18 AV 1451

Intervention Type DRUG

Tau binding agent

C-11 PiB

Intervention Type DRUG

Amyloid binding agent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

F-18 AV 1451

Tau binding agent

Intervention Type DRUG

C-11 PiB

Amyloid binding agent

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over the age of 21
* Must have an informant who will be able to provide independent evaluation of functioning
* English is primary language
* All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
* All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
* All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain

Exclusion Criteria

* If you have had a stroke or tumor that could explain your symptoms
* Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
* Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
* Subjects will be excluded if they have poor vision (20/400)
* Women that are pregnant or post-partum and breast-feeding will be excluded
* Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome
* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)

Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No